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A B S T R A C T
Background
Elevated homocysteine levels have been shown to be an independent risk factor for cardiovascular disease. However studies of homocys-
teine lowering in general and end-stage kidney disease (ESKD) populations have not demonstrated a reduction in cardiovascular event
rates. Kidney transplant recipients have high homocysteine levels, high cardiovascular event rates and, unlike the ESKDpopulation, may
achieve normalisation of homocysteine levels with homocysteine lowering therapies. Thus may benefit from homocysteine lowering
therapy.
Objectives
To evaluate the effects of established homocysteine lowering therapy on cardiovascular mortality in patients with functioning kidney
transplants.
Search methods
We searched the Cochrane Renal Group’s Specialised Register to 16 March 2015 through contact with the Trials’ Search Co-ordinator
using search terms relevant to this review.
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Selection criteria
Randomised controlled trials of any therapy that has been shown to significantly lower homocysteine levels conducted in people with
functioning kidney transplants. Studies were to be included if they compared homocysteine lowering therapy with placebo or usual
care, or compare higher versus lower doses of homocysteine lowering therapy.
Data collection and analysis
Two authors independently assessed study quality and extracted data. Results were to be expressed as the risk ratio (RR) for dichotomous
outcomes or mean difference (MD) for continuous outcomes with 95% confidence intervals (CI). Data was to be pooled using the
random effects model.
Main results
The literature search yielded 359 reports of which only one study was identified that met our inclusion criteria and reported relevant
clinical endpoints. This study randomised 4110 adult participants with a functioning kidney transplant and elevated homocysteine
levels to folic acid plus high dose B multivitamins or low dose multivitamins who were followed for a mean 4.0 years. Despite effectively
lowering homocysteine levels) in homocysteine levels at follow-up (MD -4.40 µmol/L, 95% CI -5.98 to -2.82) there was no evidence
the intervention impacted on any of the outcomes reported including cardiovascular mortality (RR 0.91, 95% CI 0.69 to 1.20), all-
cause mortality (RR 1.04, 95% CI 0.88 to 1.22), myocardial infarction (RR 1.02, 95% CI 0.77 to 1.35), stroke (RR 1.08, 95% CI
0.69 to 1.71), commencement of renal replacement therapy (RR 1.12, 95% CI 0.91 to 1.37) or all reported adverse events (RR 1.02,
95% CI 0.87 to 1.20). There was no evidence the intervention impacted on the primary endpoint of the study, a cardiovascular event
composite (RR 0.99, 95% CI 0.85 to 1.15). The study was of high quality.
Authors’ conclusions
There is no current evidence to support the use of homocysteine lowering therapy for cardiovascular disease prevention in kidney
transplant recipients.
P L A I N L A N G U A G E S U M M A R Y
Interventions for lowering plasma homocysteine levels in kidney transplant recipients
People with high homocysteine levels have higher rates of cardiovascular disease than those with homocysteine levels within the normal
range. Kidney transplant recipients have proportionately more cardiovascular disease events than the general population. The aim
of this review was to determine if homocysteine lowering therapies effectively reduce cardiovascular event rates in kidney transplant
recipients. A single study was identified that randomised 4110 adult participants with a functioning kidney transplant to homocysteine
lowering with folic acid and high dose multivitamins or to low dose multivitamins and followed them for an average of four years.
Despite effectively lowering homocysteine levels, there was no evidence of benefit for any of a range of cardiovascular events. Similarly
there was no evidence of harm.
B A C K G R O U N D
Description of the condition
Kidney transplantation is the treatment of choice for end-stage
kidney disease (ESKD), producing a life changing improvement
in quality of life and adding approximately 10 years to the life
expectancy of patients with ESKD on the transplant waiting list
(NIH2007).Despite themany developments in kidney transplan-
tation over the last 50 years, recipients of kidney transplants con-
tinue to have an excessmortality andmorbidity comparedwith the
general population (NIH 2007). Cardiovascular disease (CVD) is
a leading cause of death and late graft loss in kidney transplant
recipients (Kasiske 1996; NIH 2007). In a recent report of a RCT
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in kidney transplant recipients with 20 years follow-up, cardiovas-
cular deaths accounted for 53% of the total death rate (Gallagher
2009). Similar findings were reported by the large Assessment of
Lescol in Renal Transplantation (ALERT) study (ALERT Study
2003). An observational cohort study has also reported the cumu-
lative incidence of CVD 15 years after transplantation to be 23%
for coronary artery disease, 15% for cerebrovascular disease and
15% for peripheral vascular disease (PVD) (Kasiske 1996). The
overall risk of CVD following kidney transplantation is five times
higher than that of the general population (Kasiske 1996).
Description of the intervention
In untreated classical homocysteinuria, a homozygous genetic dis-
order of C677T MTHFR resulting in very high levels of plasma
homocysteine (100 to 400 µmol/L), death at a young age from
venous thromboembolism and malignant arterial disease is fre-
quently observed. Moreover, long-term treatments that lower ho-
mocysteine levels have been extremely effective in reducing the po-
tentially life threatening vascular risk of these patients (Yap 2003).
In addition, in the general population and Kidney transplant re-
cipients high homocysteine levels has been shown to be an in-
dependent risk factor for CVD including stroke, myocardial in-
farction (MI), atherosclerosis, arterial and venous thrombosis and
cardiovascular death in the general population (Ducloux 2000;
HSC 2002; Massy 1994; Wald 2002). In kidney transplant recip-
ients, every 1 µmol/L increase in total homocysteine is associated
with a 6% increase in the risk of developing CVD, including MI,
stroke, PVD and death (Ducloux 2000). Furthermore, hyperho-
mocysteinaemia has also been correlated to kidney allograft loss
in kidney transplant recipients (Winkelmayer 2005). The striking
benefits achieved in patients with homocysteinuria have long been
speculated to also be reproducible in other general, chronic kidney
disease (CKD) and kidney transplant recipients populations with
elevated homocysteine levels. However interventions that lowered
homocysteine levels have not yet been shown to reduce cardiovas-
cular risk in either the CKD (Jamison 2007; Vianna 2007; Wrone
2004; Zoungas 2006) or in the general population (Albert 2008;
Bonaa 2006; Lonn 2006; Schnyder 2002; Toole 2004).
How the intervention might work
Homocysteine is thought to play an active role in the pathogenesis
of atherosclerosis by damaging the endothelium and promoting
intra-arterial and venous thrombosis. There is strong experimental
evidence that hyperhomocysteinaemia produces endothelial cell
injury andproliferationofmedial smoothmuscle cells (Lang 2000;
Lentz 1996; McCully 1996; Starkebaum 1986). In addition ho-
mocysteine has been found to enhance the activity of and increase
the synthesis of clotting factors (D’Angelo 1997; Lentz 1991).
Why it is important to do this review
The role of homocysteine lowering in kidney transplant recipients
has not been established. The kidney transplant recipient group
may be the ideal group to test the homocysteine hypothesis as they
have a high cardiovascular event rate (Kasiske 1996) and unlike
the ESKD population, can achieve normal homocysteine levels
with folic acid, vitamin B12, and vitamin B6 treatment (Beaulieu
1999).
The harms of homocysteine lowering interventions have also not
been established.Whilst it is generally believed that folic acid, vita-
min B6 and B12 supplementation are safe, there are concerns that
high folic acid levels may lead to increased cancer risk (Hubner
2007). This is of particular concern in the kidney transplant recip-
ient group as they have higher absolute rates of malignancy than
the general population. Thus even a small increase in relative risk
of cancer may outweigh any potential benefits.
Efforts to reduce cardiovascular risk in kidney transplant recipients
are attractive because of the large potential benefit of treatment.
The European clinical guidelines (EBPG 2002) state the need
for more research to be conducted as there is no evidence that
reduction of homocysteine levels decreases the incidence of CVD
in kidney transplant recipients.
This meta-analysis aims to assess the benefits and harms of homo-
cysteine lowering therapy in kidney transplant recipients in order
to guide decision making and improve outcomes for this patient
population.
O B J E C T I V E S
To evaluate the effects of established homocysteine lowering ther-
apy on cardiovascular mortality in patients with functioning kid-
ney transplants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Randomised controlled trials (RCTs) and quasi-RCTs
(allocation to treatment was obtained by alteration, use of
alternate medical records, date of birth or other predictable
methods).
2. Including a minimum of 100 patient-years follow-up (to
reduce the risk of reporting or publication bias).
Studies with a sequential or cross-over design were excluded.
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Types of participants
All patients (adults and children) with a functioning kidney trans-
plant defined as a kidney transplant in situ with no requirement
for maintenance dialysis, or as defined by study authors.
Types of interventions
Studies randomising patients to any therapywhich has been shown
to significantly lower homocysteine levels were included (e.g. folic
acid, vitamin B6 and vitamin B12). Studies of regimens in which
a major mechanism of action is not thought to be homocysteine
lowering will be excluded (e.g. simvastatin plus folic acid). Com-
parisons to be investigated were as follows.
• Homocysteine lowering therapy versus placebo or usual care
• Higher versus lower dose homocysteine lowering therapy
• Any schedule of treatment
• Any route of treatment.
Types of outcome measures
Primary outcomes
• Cardiovascular mortality
Secondary outcomes
• All-cause mortality
• Cardiovascular disease
◦ Fatal and nonfatal MI
◦ Coronary revascularization
• Cerebrovascular disease
◦ Stroke
◦ Cerebrovascular revascularization
• PVD and venous thromboembolic disease
◦ Lower limb amputation
◦ Deep vein thrombosis (DVT) and pulmonary
embolism (PE)
• Kidney-specific outcomes
◦ Commencement of renal replacement therapy (RRT)
(dialysis or transplantation)
◦ Change in kidney function
• Adverse events from folic-based therapy
◦ Gastrointestinal events
◦ Dermatological events
◦ Neurological events
◦ Malignancy incidence and mortality
• Any self-reported adverse events
Search methods for identification of studies
Electronic searches
We searched the Cochrane Renal Group’s Specialised Register to
16 March 2015 through contact with the Trials’ Search Co-ordi-
nator using search terms relevant to this review. The Cochrane Re-
nal Group’s Specialised Register contains studies identified from
the following sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the
proceedings of major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies, as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts, are available in the specialised
register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of clinical practice guidelines, review articles
and relevant studies.
2. Experts in the field were contacted for additional studies.
Data collection and analysis
Selection of studies
Two authors independently assessed each reference for eligibility.
Language was not an exclusion criterion. Disagreement regarding
inclusion in the review was resolved by consensus among three
authors.
Data extraction and management
Data extraction was performed independently by two authors us-
ing a standardised data form, who independently entered the data
into RevMan 5. Where more than one publication of the study
exists, the publications with the most complete data will be in-
cluded. Where relevant outcomes were only published in earlier
versions, these data were to be used. Any discrepancy between
published versions was to be noted. The original author was to be
contacted via written correspondence for any further information
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or clarification of unclear data. Disagreements were to be resolved
by consensus among three authors.
Assessment of risk of bias in included studies
Twoauthorswere to independently assess the following itemsusing
the risk of bias assessment tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (all-cause mortality, MI, coronary
revascularization, cardiovascular death, stroke, cerebrovascular
revascularization, lower limb amputation, DVT, PE, commence-
ment of RRT), results were to be expressed as risk ratio (RR) with
95% confidence intervals (CI).
If a significant risk reductionwas found, the absolute risk reduction
with therapy was to be calculated in relation to the absolute risk
found in the placebo/comparator group.
Dealing with missing data
Where outcomes sought were reported in insufficient detail to
allow meta-analysis and further information was not forthcoming
from triallists, these outcomes were to be tabulated and assessed
with descriptive techniques and where possible the risk difference
(RD) with 95% CI was to be calculated.
If sufficient RCTs were identified, an attempt was to be made to
evaluate the risk of publication bias using a funnel plot. Attrition
bias was to be assessed using the loss/event ratio.
Assessment of heterogeneity
Heterogeneity was to be analysed using a Chi2 test on N-1 degrees
of freedom, with an alpha of 0.05 used for statistical significance
and with the I2 test (Higgins 2003). I2 values of 25%, 50% and
75% were taken to correspond to low, medium and high levels of
heterogeneity.
Assessment of reporting biases
The intention was that the risk of publication bias was to be eval-
uated using a funnel plot. Attrition bias was to be assessed using
the loss/event ratio.
Data synthesis
The intention was that data was to be pooled using the random-
effects model but the fixed-effect model would also be analysed
to ensure robustness of the model chosen and susceptibility to
outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analyseswere to be conducted to explore possible sources
of heterogeneity. Heterogeneity was to be analysed using the
Cochran Q test on N-1 degrees of freedom, with P < 0.05 used
to denote statistical significance, and the I2 test (with uncertainty
intervals). Subgroup analyses were to be conducted according to
the following characteristics.
• Gender
• Adults and children
• History of cardiac disease or diabetes mellitus
• Prior vitamin supplementation
• Concurrent vitamin supplementation
• Concomitant medications (e.g. aspirin)
• Mandatory grain fortification in the country study
conducted
• Baseline homocysteine level (≤ upper limit normal (ULN)
versus > ULN).
We intended to conduct a subgroup analysis if possible using these
characteristics. Plausible explanations for variations in treatment
effect were to be explored using subgroup analyses based on study
quality and length of follow-up.
Sensitivity analysis
Sensitivity analyses were to be conducted to ensure conclusions
were robust to decisions made during the review process such as
inclusion criteria and imputing ofmissingdata. Sensitivity analyses
were also to be conducted to assess the influence ofmethodological
quality.
R E S U L T S
Description of studies
Results of the search
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The literature search yielded a total of 359 records (Figure 1). Of
these, 44 were reviewed in full text. One study (13 reports) was
identified that met our inclusion criteria (FAVORIT Study 2006).
Figure 1. Study flow diagram
Included studies
Participants
The study randomised 4410 people aged 35 to 75 years with a
functioning kidney transplant who were at least six months post-
transplantation with stable kidney function and an elevated ho-
mocysteine level (≥ 11 µmol/L women; ≥ 12 µmol/L men). The
mean follow-up time was 4.0 years.
Roughly one third (37.2%)were female, one quarter (23.5%)were
of non-white race, one fifth had a history of cardiovascular disease
(20.0%) and twofifths had diabetesmellitus (40.5%). Participants
were recruited from the US (73%), Brazil (14.9%) and Canada
(12.1%) between August 2002 and January 2007. The vast ma-
jority of participants would have been recruited during the era
of mandatory grain fortification with folic acid which was intro-
duced in 1998 in the USA and Canada (Crider 2011) and in June
2004 in Brazil (Orioli 2011). Patients had functioning transplants
for an average of 5 ± 5.0 years standing with an average screening
eGFR of 48.8 ± 16.2 mL/min. Mean homocysteine levels were
16.4 ± 1.3 mmol/L.
Interventions
The intervention was folic acid 5.0 mg plus high (50 mg vitamin
B6; 1.0mg vitamin B12) or low (1.3mg vitamin B6; 2.0 µg vitamin
B12) dose multivitamins.
Outcomes
The primary outcome was a composite of cardiovascular disease
(cardiovascular death,MI, resuscitated sudden death, stroke, coro-
nary artery revascularization, lower extremity revascularization,
above-ankle amputation for severe arterial disease, carotid en-
darterectomy or angioplasty, abdominal aortic aneurysm repair or
renal artery revascularization). Patients commencing dialysis con-
tinued on study treatment until they reached a primary endpoint
whereupon study medication was ceased.
Excluded studies
After full text review we excluded 31 records (19 studies). The
reasons for exclusion were: wrong study design (5); wrong inter-
vention (6) or < 100 patient-years. See Characteristics of excluded
studies.
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Risk of bias in included studies
The identified study has an overall low risk of bias (Risk of bias in
included studies).
Effects of interventions
Meta-analysis was not applied as only a single eligible study was
identified (FAVORIT Study 2006).
FAVORIT Study 2006 found that, based on a subgroup of 143
participants, high dose folic acid and B group vitamins signif-
icantly lowered homocysteine levels (Analysis 1.1 (143 partici-
pants): -4.40 µmol/L, 95% CI -5.98 to -2.82).
Despite effectively lowering homocysteine levels there was no ev-
idence the intervention impacted on any of the outcomes for this
review.
• Cardiovascular mortality (Analysis 1.2 (4110 participants):
RR 0.91, 95% CI 0.69 to 1.20)
• All-cause mortality (Analysis 1.3 (4110 participants): RR
1.04, 95% CI 0.88 to 1.22)
• MI (Analysis 1.4 (4110 participants): RR 1.02, 95% CI
0.77 to 1.35)
• Coronary revascularization (Analysis 1.5 (4110
participants): RR 0.93, 95% CI 0.73 to 1.19)
• Stroke (Analysis 1.6 (4110 participants): RR 1.08, 95% CI
0.69 to 1.71)
• Cerebrovascular revascularization (defined in the FAVORIT
Study 2006 as carotid endarterectomy or angioplasty) (Analysis
1.7 (4110 participants): RR 1.11, 95% CI 0.45 to 2.73)
• Commencement of RRT (defined in the FAVORIT Study
2006 as dialysis-dependent kidney failure) (Analysis 1.8 (4110
participants): RR 1.12, 95% CI 0.91 to 1.37)
• Adverse gastrointestinal events (Analysis 1.9 (4110
participants): RR 1.06, 95% CI 0.83 to 1.36)
• All reported adverse events (Analysis 1.10 (4110
participants): RR 1.02, 95% CI 0.87 to 1.20).
No data were reported in the FAVORIT Study 2006 for change
in kidney function, deep vein thrombosis and PE, lower limb am-
putation per se (although it was included in a PVD composite),
adverse dermatological events, adverse neurological events or ad-
verse malignant events.
There was no evidence the intervention impacted on the primary
endpoint of the FAVORIT Study 2006, a cardiovascular event
composite (RR 0.99, 95% CI 0.85 to 1.15), nor on any of the
secondary endpoints not mentioned above including resuscitated
sudden death (RR 0.80, 95% CI 0.32 to 2.02), PVD defined as
lower extremity revascularization or amputation above the ankle
for severe arterial disease (RR 1.17, 95%CI 0.81 to 1.67), abdom-
inal aortic aneurysm repair (RR 0.60, 95% CI 0.14 to 2.50) and
renal artery revascularization (RR 1.28, 95% CI 0.48 to 3.44).
D I S C U S S I O N
Summary of main results
This review identified only one completed study that met our in-
clusion criteria for examining the effectiveness of homocysteine
lowering in kidney transplant recipients. In this study, there was no
evidence that homocysteine lowering had an effect on any of the
assessed cardiovascular outcomes, including cardiovascular mor-
tality, MI, and stroke, other clinical outcomes, including all-cause
mortality, requirement for dialysis treatment or access thrombosis,
nor on adverse effects.
Overall completeness and applicability of
evidence
Beyond kidney transplantation, the impact of homocysteine has
been studied in people with other categories of kidney disease. A
systematic review performed by our group examined the impact of
folic acid-based homocysteine lowering in people with any type of
kidney disease categorised as ESKD,CKDand functioning kidney
transplantation (Jardine 2012). Eleven studies were identified re-
porting 3045 cardiovascular events among 10,863 participants of
which the FAVORIT Study 2006 contributed 4110 participants.
There was no evidence homocysteine lowering reduced the pri-
mary cardiovascular composite endpoint either overall (RR 0.97,
95%CI 0.92 to 1.03) nor in any of three defined categories of kid-
ney disease (P = 0.785). This data is consistent with studies in the
general population, where folic acid based homocysteine lowering
has also not been found to prevent cardiovascular events in large
RCTs. The B-Vitamin Treatment Trialists’ Collaboration has per-
formed two individual patient level data analyses of larger studies
randomising participants to folate-containing B group vitamins
(Clarke 2010; Vollset 2013) although neither were able to include
the FAVORIT Study 2006. The first primarily analysed the im-
pact on the incidence of vascular disease in 37,485 participants in
eight studies while the second assessed cancer incidence in 49,621
participants in 13 studies. Over a median of five years of treat-
ment, folate-containing B group vitamin supplementation had no
impact on major vascular events (RR 1.01, 95% CI 0.97 to 1.05)
or mortality (RR 1.02, 95% CI 0.97 to 1.08) despite an average
25% reduction in homocysteine levels. There was no evidence of
heterogeneity in subgroup analyses comparing the impact of the
intervention according to serum creatinine (< 80, 80 to 94 and
≥ 95 µmol/L). Similarly there was no impact on cancer incidence
over average five years treatment duration (RR 1.06, 95% CI 0.99
to 1.13). In combination these studies appear to have effectively
excluded any beneficial cardiovascular effect of homocysteine low-
ering therapy in the general population and in people with kidney
disease.
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Quality of the evidence
The included study (FAVORIT Study 2006) was of assessed as
high quality.
Potential biases in the review process
We specifically included only RCTs with a minimum of 100 pa-
tient-years follow-up in our inclusion criteria to reduce the risk
of reporting or publication bias that may be associated with small
studies (Egger 1997). To investigate the impact of the 100 pa-
tient-year criteria on our results, we modified our inclusion crite-
ria to include studies of any follow-up duration that met all other
search criteria in a sensitivity analysis. Excluding the 100 patient-
year minimum requirement resulted in identification of an extra
six studies (Beaulieu 1999; Biagini 2002; Bostom 1997; Marcucci
2002; Perez 2004; Xu 2005a).The intervention used in these stud-
ies was either folic acid or folic acid, vitamin B6 and vitamin B12.
Follow-up ranged from three to 30 patient-years. Baseline homo-
cysteine levels ranged from 17 to 30 µmol/L (compared with levels
of 100 to 400µmol/L reported in classical homocysteinuria). Four
studies found a significant decrease in fasting homocysteine lev-
els with treatment compared with placebo/lower dose (Marcucci
2002, Beaulieu 1999, Xu 2005a, Bostom 1997). Perez 2004 com-
pared standard and supraphysiological doses of folic acid, vitamin
B6 and vitamin B12 and found no significant difference in homo-
cysteine levels between the groups. Some of these studies did not
report baseline and achieved homocysteine levels for each group,
which prevented their combination using meta-analysis (Bostom
1997; Perez 2004; Xu 2005a). Marcucci 2002 reported a signif-
icant decrease in carotid intima-media thickness (cIMT) in the
treatment arm (0.95 ± 0.20 mm versus 0.64 ± 0.17 mm; P <
0.0001) and an increase in cIMT in the placebo group (0.71 ±
0.16 mm versus 0.87 ± 0.19 mm; P < 0.05). Xu 2005a found a
significant increase in endothelium dependent and independent
vasodilatation response following the intervention (12.2% ± 4.6%
versus 8.8% ± 5.2%, t = 2.9, P < 0/01 and 17.6% ± 3.9% versus
12.2% ± 4.7%, t = 3.4, P < 0.01) and there were no significant
changes observed in controls. None of these RCTs reported the
defined clinical events and therefore could not contribute to our
planned analyses. Therefore, regardless of the patient-year param-
eter in our inclusion criteria, we were unable to findmore than one
completed study that evaluated the effect of homocysteine low-
ering therapy on cardiovascular end points rather than surrogate
markers for cardiovascular disease.
Agreements and disagreements with other
studies or reviews
The KDIGO 2009 and CARI 2012 for the care of people with
functioning kidney transplants do not comment on folic acid
or B vitamin supplementation. The UK Renal Association sug-
gests offering folic acid and B group vitamin supplementation
to patients with kidney disease considered at risk of nutritional
deficiency but notes insufficient evidence to recommend supra-
physiological supplementation for vascular risk modification (The
Renal Association 2010). The guidelines noted the (then) ongo-
ing FAVORIT Study 2006 would supply evidence for people with
functioning kidney transplants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no current evidence to support the use of homocysteine
lowering therapy for cardiovascular disease prevention in kidney
transplant recipients.
Implications for research
Research focusing on mechanisms to reduce cardiovascular disease
events in kidney transplant recipients is warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
FAVORIT Study 2006
Methods • Study design: parallel RCT
• Duration of study: August 2002 to June 2009
• Duration of follow-up: mean follow-up 4.0 ± 1.5 years
Participants • Country: Brazil, Canada, USA
• Setting: 30 clinical sites
• Inclusion criteria: 6 months or more post kidney transplantation; aged 35 to 75
years; CrCl ≥ 30 mL/min for participants recruited prior to July 2005, thence ≥ 30
mL/min (men) or 25 mL/min (women); homocysteine level ≥ 12.0 µmol/L (men) or
≥11.0 µmol/L (women); provision of informed consent; cognitive function adequate
for patient to give accurate information; adequate transportation facilities; geographic
accessibility for follow-up; within 120 days of screening
• Number: treatment group (2056); control group (2054)
• Mean age ± SD (years): treatment group (52 ± 9.4); control group (52 ± 9.5)
• Sex (M/F): treatment group (1289/767); control group (1293/761)
• Exclusion criteria: presence of cancer, end-stage congestive heart failure, liver, or
pulmonary disease, progressive human immunodeficiency virus or other chronic
wasting illness, which in the opinion of the study physician would limit the life
expectancy of the patient to less than 2 years or prevent evaluation of recurrent or de
novo CVD; other conditions that prevent reliable participation in the study (refractory
depression, severe cognitive impairment, or alcoholism or other substance abuse);
history of solid organ transplant other than the kidney or pancreas; pregnant or
lactating women or women of childbearing potential not practicing birth control; < 3
months post-acute MI or stroke, or < 3 months post-coronary artery, renal artery, or
lower extremity artery percutaneous transluminal coronary angioplasty, or lower
extremity amputation; less than 6 months post-coronary artery bypass graft surgery,
abdominal aortic aneurysm; participation in another clinical study specifically
involving CVD risk factor management
Interventions Treatment group
• High dose B group multivitamin
◦ 5 mg folic acid
◦ 50 mg vitamin B6
◦ 1mg vitamin B12
Control group
• Low dose multivitamin
◦ No folic acid
◦ 1.4 mg vitamin B6
◦ 2.0 µg vitamin B12
Other information
• Both vitamin preparations contained 1.5 mg vitamin B1, 1.5 mg vitamin B2, 60
mg vitamin C, 30 µg d-Biotin, 20 mg niacinamide and 10 mg pantothenic acid
• Participants continued on their intervention until study end or, in the case of
those who developed dialysis-dependent ESKD, until the occurrence of their first
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FAVORIT Study 2006 (Continued)
primary endpoint
Outcomes • Primary composite outcome: arteriosclerotic cardiovascular disease outcome
(cardiovascular disease death, MI, resuscitated sudden death, stroke, coronary artery
revascularization, lower extremity revascularization or, for severe arterial disease,
amputation above the ankle, carotid endarterectomy or angioplasty, abdominal aortic
aneurysm repair, or renal artery revascularization)
• Secondary outcomes
◦ All-cause mortality
◦ Dialysis-dependent kidney failure
◦ Individual components of the primary outcome
◦ ’relevant’ combinations of the components of the primary outcome
Funding source • Government funded support: National Institute of Diabetes and Digestive and
Kidney Diseases, the National Institutes of Health. The Office of Dietary
Supplements, National Institutes of Health
• Commercial: Manufacture of multivitamin preparations
Presence or absence of grain fortification • Mandatory grain fortification status: mandatory fortification of grain was in place
in the US, Canada for the duration of the study, and in Brazil from June 2004
Notes • The study reports outcomes both according to intention-to-treat principles and
outcomes censored 3 months after the return to dialysis. In this analysis, we have
included the intention-to-treat outcomes.
• The study was concluded after an interim analysis when the Data Safety and
Monitoring Board recommended the study be concluded as it had ’conclusively
answered its original hypothesis’.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization by permuted block, strat-
ified by clinical site”. Two different block
sizes were used
Allocation concealment (selection bias) Low risk “Randomization ... was performed through
the data management system. Because the
need for emergency unblinding was ex-
pected to be low, unblinding codes were
stored securely at the Data Coordinating
Center, accessible only to authorized staff.
”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a placebo-controlled RCT with
both multivitamin preparations formu-
lated to be similar in appearance and smell.
Blinding was explicitly tested by survey of
participants and study coordinators with
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FAVORIT Study 2006 (Continued)
49% of each group providing incorrect
guesses of intervention allocation
“The trial was a .. double blind, randomised
clinical trial”. “Both multivitamins [stan-
dard and low dose] were formulated to be
similar in appearance and odor to facilitate
blinding”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The first 4 components of the primary out-
come (cardiovascular death, MI, resusci-
tated sudden death and stroke) were cen-
trally reviewed and adjudicated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Completeness of follow-up: deceased (493)
; complete follow-up to June 2009 (2788);
incomplete follow-up to June 2009 (822);
no follow-up (7)
Withdrawal of consent: treatment group
(198/2056); control group (171/2054)
Selective reporting (reporting bias) Low risk Event data for all the primary and sec-
ondary outcomes according to intention-
to-treat are reported
Other bias Low risk No other biases detected
CrCl - creatinine clearance; ESKD - end-stage kidney disease; MI - myocardial infarction; RCT - randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ardalan 2003 Not RCT
Austen 2006 Cross-over study
Beaulieu 1999 < 100 patient-years. No clinical events, only plasma homocysteine levels
Biagini 2002 < 100 patient-years. No clinical events, only carotid intima-media thickness
Bostom 1997 < 100 patient-years. No clinical events, only plasma homocysteine levels
Bostom 2000 Not a comparison of homocysteine lowering
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(Continued)
Jurewicz 2003 Not a comparison of homocysteine lowering
Juskowa 2006 Not a comparison of homocysteine lowering
LANDMARK 2 Study 2009 Not a comparison of homocysteine lowering
Lash 1998 Not a comparison of homocysteine lowering
Manrique 2005 < 100 patient-years
Marcucci 2002 < 100 patient-years. No clinical events, only carotid intima-media thickness
Nafar 2009 < 100 patient-years. This study has been terminated according to ClinicalTrials.gov information
Perez 2004 < 100 patient-years. No clinical events. Only clinical markers such as lipid profile
Rymarz 2009 Sequential or cross-over design
Savaj 2002 Not RCT
Shemin 2001 Not RCT
Teplan 2003b Not homocysteine lowering (hypoenergetic hypolipidaemic diet and corticosteroids withdrawal)
Xu 2005a < 100 patient-years. No clinical events. Only plasma homocysteine levels and endothelium dependent
and independent vasodilation responses
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D A T A A N D A N A L Y S E S
Comparison 1. Folic acid-based homocysteine lowering versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Achieved change in
homocysteine levels
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Cardiovascular mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 All-cause mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Myocardial infarction (fatal and
non-fatal)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Coronary revascularization 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Stroke (fatal and non-fatal) 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Cerebrovascular revascularization 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 Commencement of renal
replacement therapy
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 Adverse events: gastrointestinal 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
10 All reported adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 1 Achieved
change in homocysteine levels.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 1 Achieved change in homocysteine levels
Study or subgroup Folic acid-based Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
FAVORIT Study 2006 72 -4.6 (4.5) 71 -0.2 (5.1) -4.40 [ -5.98, -2.82 ]
-10 -5 0 5 10
Favours folic acid-based Favours control
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Analysis 1.2. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 2
Cardiovascular mortality.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 2 Cardiovascular mortality
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 91/2056 100/2054 0.91 [ 0.69, 1.20 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
Analysis 1.3. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 3 All-cause
mortality.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 3 All-cause mortality
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 251/2056 242/2054 1.04 [ 0.88, 1.22 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
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Analysis 1.4. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 4 Myocardial
infarction (fatal and non-fatal).
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 4 Myocardial infarction (fatal and non-fatal)
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 96/2056 94/2054 1.02 [ 0.77, 1.35 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
Analysis 1.5. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 5 Coronary
revascularization.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 5 Coronary revascularization
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 116/2056 124/2054 0.93 [ 0.73, 1.19 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
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Analysis 1.6. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 6 Stroke
(fatal and non-fatal).
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 6 Stroke (fatal and non-fatal)
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 38/2056 35/2054 1.08 [ 0.69, 1.71 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
Analysis 1.7. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 7
Cerebrovascular revascularization.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 7 Cerebrovascular revascularization
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 10/2056 9/2054 1.11 [ 0.45, 2.73 ]
0.2 0.5 1 2 5
Favours folic acid-based Favours control
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Analysis 1.8. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 8
Commencement of renal replacement therapy.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 8 Commencement of renal replacement therapy
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 181/2056 162/2054 1.12 [ 0.91, 1.37 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
Analysis 1.9. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 9 Adverse
events: gastrointestinal.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 9 Adverse events: gastrointestinal
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 121/2056 114/2054 1.06 [ 0.83, 1.36 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
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Analysis 1.10. Comparison 1 Folic acid-based homocysteine lowering versus control, Outcome 10 All
reported adverse events.
Review: Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Comparison: 1 Folic acid-based homocysteine lowering versus control
Outcome: 10 All reported adverse events
Study or subgroup Folic acid-based Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAVORIT Study 2006 269/2056 263/2054 1.02 [ 0.87, 1.20 ]
0.5 0.7 1 1.5 2
Favours folic acid-based Favours control
A P P E N D I C E S
Appendix 1. Electronic search strategies
Databases Search terms
CENTRAL 1. MeSH descriptor: [Homocysteine] explode all trees
2. MeSH descriptor: [Hyperhomocysteinemia] this term only
3. homocysteine* in Trials
4. hyperhomocysteine* in Trials
5. #1 or #2 or #3 or #4 in Trials
6. MeSH descriptor: [Kidney Transplantation] this term only
7. kidney transplant*:ti,ab,kw (Word variations have been searched)
8. renal transplant*:ti,ab,kw (Word variations have been searched)
9. #6 and #7 and #8
10. #5 and #8
MEDLINE 1. Kidney Transplantation/
2. exp Homocysteine/
3. Hyperhomocysteinemia/
4. hyperhomocystein$.tw.
5. homocystein$.tw.
6. or/2-5
7. and/1,6
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(Continued)
EMBASE 1. exp kidney transplantation/
2. Homocysteine/
3. Hyperhomocysteinemia/
4. hyperhomocysteine$.tw.
5. homocystein$.tw.
6. or/2-5 7.
7. and/1,6
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
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(Continued)
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
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(Continued)
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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